13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002054410
Total reported value
$366.5M
$366.5M
21 檔
24.4%
As reported in its official Q2 2025 Form 13F filing, Acorn Capital Advisors, LLC's tracked investment portfolio stood at $366.5M with 21 total positions.
During Q2 2025, Acorn Capital Advisors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 19.24% | +0.17% | — | |
| 2 | URGN | UroGen Pharma Ltd. | Stock-Other | 11.29% | +8.25% | -16.92% | |
| 3 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 10.09% | — | +5.67% | |
| 4 | PBYI | Puma Biotechnology Inc | Stock-Other | 9.27% | +1.64% | +4.85% | |
| 5 | CADL | Candel Therapeutics Inc | Stock-Other | 8.54% | +4.94% | +19.90% | |
| 6 | TRVI | Trevi Therapeutics Inc | Stock-Other | 7.67% | +3.65% | — | |
| 7 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 4.81% | -26.17% | EXIT | |
| 8 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 4.44% | +0.19% | +97.24% | |
| 9 | HELP | Cybin Inc | Stock-Other | 4.03% | +0.68% | — | |
| 10 | BCAX | Bicara Therapeutics Inc | Stock-Other | 3.91% | +1.57% | — | |
| 11 | TARA | Protara Therapeutic Inc | Stock-Other | 3.47% | -0.76% | +36.91% | |
| 12 | CRDF | Cardiff Oncology Inc | Stock-Other | 2.90% | -0.81% | EXIT | |
| 13 | AURA | Aura Biosciences Inc | Stock-Other | 2.44% | +0.67% | +0.89% | |
| 14 | VSTM | Verastem Inc | Stock-Other | 2.12% | -0.68% | — | |
| 15 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 1.39% | +0.30% | — | |
| 16 | BCABGBP | Bioatla Inc | Stock-Other | 1.25% | -0.13% | +19.92% | |
| 17 | ✓ | Mural Oncology Pub LTD Co | Stock-Other | 1.06% | — | -48.51% | |
| 18 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.79% | — | -6.28% | |
| 19 | QTTB | Q32 Bio Inc | Stock-Other | 0.78% | +0.18% | — | |
| 20 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.32% | — | — | |
| 21 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.19% | -0.27% | EXIT |
According to official SEC Form 13F filings, Acorn Capital Advisors, LLC reported a total U.S. public equity portfolio value of $366.5M across 21 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, URGN, YMABUSD) accounted for 24.4% of total reported equity market value during Q2 2025.
During Q2 2025, Acorn Capital Advisors, LLC's top holdings by market value included CGON (19.2%)、URGN (11.3%)、YMABUSD (10.1%). The largest single position, CGON, represented 19.2% of total portfolio value.
In Q2 2025, Acorn Capital Advisors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.